NCT03848832终止3 期
A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
研究概览
简要总结
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant (if possessing adequate understanding, in the investigator's opinion) and/or their parent(s)/legal representative is willing and able to give informed consent/assent for participation in the trial.
- •Participant and their caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements (including the completion of all caregiver assessments by the same caregiver throughout the trial).
- •Participant must weigh at least 10 kilograms.
- •Clinical diagnosis of Rett syndrome (typical or atypical), defined according to RettSearch Consortium criteria
- •Confirmed pathogenic genetic mutation of the MECP2 gene
- •Participant must be post-regression (≥ 6 months since last loss of hand use or verbal language or gross motor regression).
- •Participant must have a disease severity of between 10 and 36, defined according to the Clinical Severity Scale (CSS).
- •All medications or interventions (including antiepileptic drugs [AEDs] and non-pharmacological interventions - dietary supplements, probiotics, physical therapy, speech therapy, etc.) for Rett syndrome-related symptoms must have been stable for 4 weeks prior to screening and the participant/caregiver must be willing to maintain a stable regimen throughout the trial.
- •Ability to swallow the investigational medicinal product (IMP) provided as a liquid solution, or the ability for IMP to be delivered via gastrostomy (G) or nasogastric (NG) feeding tube (only G-or NG-tubes made from polyurethane or silicon are allowed)
- •Participant and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
- •Participant and/or parent(s)/legal representative is willing to allow the participant's primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial, if the primary care practitioner/consultant is different than the investigator.
排除标准
- •Participant meets exclusion criteria for Rett syndrome diagnosis (traumatic brain injury, neurometabolic disease, or severe infection that causes neurological problems; grossly abnormal psychomotor development in the first 6 months of life).
- •Participant has clinically significant abnormal laboratory values, in the investigator's opinion.
- •Participant is taking more than 2 concurrent AEDs.
- •Any history of suicidal behavior or any suicidal ideation in the last month or at screening
- •Clinically relevant abnormalities in the electrocardiogram (ECG) measured at screening or randomization
- •Concurrent cardiovascular conditions which will, in the investigator's opinion, interfere with the ability to assess their ECGs or put the participant at risk because of participation in the trial
- •First or second degree relative with a history of significant ECG abnormalities, in the opinion of the investigator (e.g. premature cardiac arrest, sudden death)
- •Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP (active or placebo), such as sesame oil
- •Participant has moderately impaired hepatic function at screening, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN) or total bilirubin > 2 × ULN.
- •Participant is of childbearing potential, unless willing to ensure that they or their partner use a highly effective method of birth control (e.g., combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, or transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, or implantable], intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner, sexual abstinence) during the trial and for 3 months thereafter.
- •Pregnant (positive pregnancy test) or lactating
- •Received an IMP within the 3 months prior to screening
- •Participant has been taking felbamate for less than 1 year prior to screening.
- •Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®), or cannabidiol oral solutions (including CBD-OS [GWP42003-P]) within the 3 months prior to screening and is unwilling to abstain for the duration of the trial
- •Participant has a positive delta-9-tetrahydrocannabinol (THC) test at screening.
- •Any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory) or significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the trial, may influence the result of the trial, or the participant's ability to participate in the trial
- •Any abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if she took part in the trial
- •Participant has been previously randomized into this trial.
- •Participant has traveled outside the country of residence planned during the trial.
研究组 & 干预措施
5 milligrams per kilogram per day (mg/kg/day) GWP42003-P
Experimental
100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
干预措施: GWP42003-P (Drug)
15 mg/kg/day GWP42003-P
Experimental
100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
干预措施: GWP42003-P (Drug)
Placebo
Placebo Comparator
Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
时间窗: Baseline; Week 24
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity.
次要结局
- Change From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo(Baseline; Week 24)
- Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24(Baseline; Week 24)
- Change From Baseline in Mean Clinician Global Impressions - Severity (CGI-S) Score at Week 24(Baseline; Week 24)
- Change From Baseline in Mean 9-items Motor Behavioral Assessment (MBA-9) Total Score and Subscale Scores at Week 24(Baseline; Week 24)
- Change From Baseline in Mean RSBQ Subscale Scores at Week 24(Baseline; Week 24)
- Change From Baseline in Mean Children's Sleep Habits Questionnaire (CSHQ) Total Score and Subscale Scores at Week 24(Baseline; Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi SyndromePrader-Willi SyndromeNCT02844933Radius Pharmaceuticals, Inc.7
已完成
不适用
Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.Covid 19NCT04828668Endourage, LLC32
进行中（未招募）
3 期
A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory EpilepsyEpilepsyNCT02783092Antonio Waldo Zuardi126
Unknown
2 期
CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate SymptomsSARS-CoV2NCT04467918University of Sao Paulo100
Unknown
不适用
Efficacy Trial of Oral Tetrahydrocannabinol in Patients With FibromyalgiaFibromyalgiaNCT01149018Hadassah Medical Organization80